IRadimed Corporation
IRadimed Corporation Fundamental Analysis
IRadimed Corporation (IRMD) shows strong financial fundamentals with a PE ratio of 46.74, profit margin of 27.36%, and ROE of 24.48%. The company generates $0.1B in annual revenue with strong year-over-year growth of 14.43%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 82.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze IRMD's fundamental strength across five key dimensions:
Efficiency Score
ExcellentIRMD demonstrates superior asset utilization.
Valuation Score
WeakIRMD trades at a premium to fair value.
Growth Score
ExcellentIRMD delivers strong and consistent growth momentum.
Financial Health Score
ExcellentIRMD maintains a strong and stable balance sheet.
Profitability Score
ExcellentIRMD achieves industry-leading margins.
Key Financial Metrics
Is IRMD Expensive or Cheap?
P/E Ratio
IRMD trades at 46.74 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, IRMD's PEG of 2.53 indicates potential overvaluation.
Price to Book
The market values IRadimed Corporation at 11.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 37.97 times EBITDA. This signals the market has high growth expectations.
How Well Does IRMD Make Money?
Net Profit Margin
For every $100 in sales, IRadimed Corporation keeps $27.36 as profit after all expenses.
Operating Margin
Core operations generate 32.40 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $24.48 in profit for every $100 of shareholder equity.
ROA
IRadimed Corporation generates $20.64 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
IRadimed Corporation generates strong operating cash flow of $28.94M, reflecting robust business health.
Free Cash Flow
IRadimed Corporation generates strong free cash flow of $24.10M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.89 in free cash annually.
FCF Yield
IRMD converts 2.17% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
46.74
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.53
vs 25 benchmark
P/B Ratio
Price to book value ratio
11.20
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.79
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.13
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.24
vs 25 benchmark
ROA
Return on assets percentage
0.21
vs 25 benchmark
ROCE
Return on capital employed
0.27
vs 25 benchmark
How IRMD Stacks Against Its Sector Peers
| Metric | IRMD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 46.74 | 28.62 | Worse (Expensive) |
| ROE | 24.48% | 783.00% | Weak |
| Net Margin | 27.36% | -48181.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 7.13 | 4.12 | Strong Liquidity |
| ROA | 20.64% | -21914.00% (disorted) | Strong |
IRMD outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews IRadimed Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
151.82%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
1464.83%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
308.66%
Industry Style: Defensive, Growth, Innovation
High Growth